12:00 AM
 | 
Nov 11, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/8 cls
Curis Inc. (NASDAQ:CRIS) BMO Capital Markets Jim Birchenough Downgrade Market perform (from outperform) -30% $2.75
Birchenough also lowered his target to $3 from $8 after FDA placed a partial clinical hold on a Phase I trial with CUDC-427 to treat solid tumors or lymphoma. The decision followed a patient's death from liver failure a month after discontinuing treatment with the small molecule inhibitor...

Read the full 516 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >